ByteDance spin-off Anew Labs raises US$290m as AI drug developers enjoy fundraising boom
Anew Labs, a Shanghai-based AI drug discovery firm spun off from ByteDance, has secured US$290 million in funding. This round values the company at US$1.5 billion. Investors include HSG, IDG Capital, and 5Y Capital, with ByteDance retaining a 56 percent stake. Anew Labs develops AI models for biomolecular structure prediction and design, including AnewFold and Protenix.
Anew Labs' US$290 million raise, valuing it at US$1.5 billion, underscores China's aggressive push into AI drug discovery. ByteDance's continued 56 percent stake shows a commitment to this sector. This reflects a broader trend of major Chinese tech firms incubating and backing AI ventures. They seek to diversify beyond core internet services.
The focus on biomolecular prediction, including an open-source reproduction of AlphaFold 3, positions Anew Labs as a direct challenger to Google DeepMind and Isomorphic Labs. This competition is crucial for China's biotech self-sufficiency. It also provides domestic pharmaceutical companies with advanced tools. The funding boom will accelerate drug development within the region.
The test for Anew Labs is its ability to translate model predictions into tangible drug candidates. Many AI drug discovery firms face this hurdle. Investors will watch for clinical trial progress and pipeline development. This will validate the US$1.5 billion valuation.
Related reading
6 stories
Will AI adoption shrink office space? Asia-Pacific firms are on the fence in survey
Huawei brings near-packaged optics to AI with Atlas 960E superpod
Chip foundries better insulated in an AI slowdown than Asia-Pacific tech peers, S&P says
OCBC Extends Bank of Ningbo Partnership as 20 Percent Shareholder
China to see major shift to Huawei for AI model training in 2027: rotating chair
